The company anticipates that FDA could authorise NuThrax for emergency use as early as 2018, triggering deliveries of NuThrax to the SNS in 2019. The contract also includes procurement options for the delivery of an additional 7.5 million to 50 million doses of NuThrax to the SNS, valued from approximately $ 255 million to up to $ 1.4 billion, respectively, and options for an additional clinical study and post-marketing commitments valued at $ 48 million, which if both were to be exercised in full, would increase the total contract value to up to $1.6 billion.